

## СПИСОК ЛИТЕРАТУРЫ

1. Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes Res Clin Pract.* 2022;183:109–119. DOI: 10.1016/j.diabres.2021.109119
2. Karimian Pour N., Adeli K. Insulin silences apolipoprotein B mRNA translation by inducing intracellular traffic into cytoplasmic RNA granules. *Biochemistry.* 2011;50(32):6942–6950. DOI: 10.1021/bi200711v
3. Berger J.M., Moon Y.A. Increased hepatic lipogenesis elevates liver cholesterol content. *Molecules and Cells.* 2021;44(2):116–125. DOI: 10.14348/molcells.2021.2147
4. Vergès B. Pathophysiology of diabetic dyslipidaemia: where are we? *Diabetologia.* 2015;58(5):886–899. DOI: 10.1007/s00125-015-3525-8
5. Catapano A.L., Graham I., De Backer G., et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. *European heart journal.* 2016; 37(39):2999–3058. DOI: 10.1093/eurheartj/ehw272
6. Chehade J.M., Gladysz M., Mooradian A.D. Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management. *Drugs.* 2013;73(4):327–339. DOI: 10.1007/s40265-013-0023-5
7. Case B.C., Bress A.P., Kolm P., et al. The economic burden of hypertriglyceridemia among US adults with diabetes or atherosclerotic cardiovascular disease on statin therapy. *Journal of clinical lipidology.* 2019;13(5):754–761. DOI: 10.1016/j.jacl.2019.07.004
8. Ginsberg H.N, Packard C.J, Chapman M.J. et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies — a consensus statement from the European Atherosclerosis Society. *Eur Heart J.* 2021; 42(47): 4791–4806. DOI: 10.1093/eurheartj/ehab551
9. Metelskaya V.A., Shalnova S.A., Deev A.D. et al. On behalf of the participants of the ESSE-RF study. Analysis of atherogenic dyslipidemias prevalence among population of Russian Federation (results of the ESSE-RF Study). Russian (Метельская В.А., Шальнова С.А., Деев А.Д., и др. Анализ распространенности показателей, характеризующих атерогенность спектра липопротеинов, у жителей Российской Федерации (по данным исследования ЭССЕ-РФ). Профилактическая медицина. 2016. 19(1): 15–23). DOI: 10.17116/profmed201619115-23
10. Meshkov A.N., Ershova A.I., Deev A.D., et al. Distribution of lipid profile values in economically active men and women in Russian Federation: results of the ESSE-RF study for the years 2012–2014. *Cardiovascular Therapy and Prevention.* 2017;16(4):62–67. Russian (Мешков А.Н., Ершова А.И., Деев А.И. и др. Распределение показателей липидного спектра у мужчин и женщин трудоспособного возраста в Российской Федерации: результаты исследования ЭССЕ-РФ за 2012–2014 гг. Кардиоваскулярная терапия и профилактика. 2017. 16(4): 62–67). DOI: 10.15829/1728-8800-2017-4-62-67
11. Ruiz-García A, Arranz-Martínez E, López-Uriarte B, et al. Prevalence of hypertriglyceridemia in adults and related cardiometabolic factors. SIMETAP-HTG study. *Clin Investig Arterioscler.* 2020;32(6):242–255. DOI: 10.1016/j.arteri.2020.04.001
12. Salomaa VV, Tuomilehto J, Jauhiainen M, et al. Hypertriglyceridemia in different degrees of glucose intolerance in a Finnish population-based study. *Diabetes Care.* 1992;15(5):657–65. DOI: 10.2337/diacare.15.5.657
13. Dagneb B., Yeshaw Y., Geremew D. et al. Hypertriglyceridemia and Other Plasma Lipid Profile Abnormalities among People Living with Diabetes Mellitus in Ethiopia: A Systematic Review and Meta-Analysis. *Biomed Res Int.* 2021: 7389076. DOI: 10.1155/2021/7389076
14. Karpov YA. On behalf of participants of the Prometheus study. Prevalence of Hypertriglyceridemia: New Data Across the Russian Population. The PROMETHEUS Study. *Kardiologia.* 2016;56(7):63–71.
15. Borén J, Chapman MJ, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. *Eur Heart J.* 2020; 41(24): 2313–2330. DOI: 10.1093/eurheartj/ehz962
16. Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. *J Lipid Res* 1996; 37(4):693–707.
17. Dallinga-Thie GM, Kroon J, Boren J, Chapman MJ. Triglyceride-rich lipoproteins and remnants: targets for therapy? *Curr Cardiol Rep/* 2016; 18(7):670.
18. Chapman MJ, Ginsberg HN, Amarenco P, et al. European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. *Eur Heart J.* 2011;32(11):1345–1361.
19. Borén J, Watts GF, Adiels M, et al. Kinetic and related determinants of plasma triglyceride concentration in abdominal obesity. Multicenter Tracer Kinetic Study. *Arterioscler Thromb Vasc Biol.* 2015; 35(10):2218–2224.
20. Blonde L, Umpierrez G. E., S. Reddy S., et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update. *Endocr Pract.* 2022 Oct; 28(10): 923–1049. DOI: 10.1016/j.eprac.2022.08.002
21. Nakamura T., Obata J., Hirano M. et al. Predictive Value of Remnant Lipoprotein for Cardiovascular Events in Patients with Coronary Artery Disease after Achievement of LDLcholesterol Goals. *Atherosclerosis.* 2011;218:163–167. DOI: 10.1016/j.atherosclerosis.2011.04.040
22. Gaggini M, Gorini F, Vassalle C. Lipids in Atherosclerosis: Pathophysiology and the Role of Calculated Lipid Indices in Assessing Cardiovascular Risk in Patients with

- Hyperlipidemia. *Int J Mol Sci.* 2023 Jan; 24(1): 75. DOI: 10.3390/ijms24010075
23. Ezhov MV, Kukharchuk VV, Sergienko IV. Clinical recommendations "Lipid metabolism disorders". Russian Society of Cardiology. M., 2023. Russian (Ежов М.В., Кухарчук В.В., Сергиенко И.В. и др. Клинические рекомендации «Нарушения липидного обмена». Российское кардиологическое общество. М., 2023).
24. Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Atherosclerosis.* 2019;290:140–205. DOI: 10.1016/j.atherosclerosis.2019.08.014
25. Hegele RA, Borén J, Ginsberg HN, et al. Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. *Lancet.* 2020; 8(1): 50–67. DOI: 10.1016/S2213-8587(19)30264-5
26. Zhao Z, Tuakli-Wosornu Y, Lagace TA et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. *Am J Hum Genet.* 2006; 79: 514–523.
27. Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. *Nat Genet.* 2013; 45(11): 1345–1352. DOI: 10.1038/ng.279
28. Kathiresan S, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. *Nat Genet.* 2008;40:189–97. DOI: 10.1038/ng.2480.
29. Deloukas P, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. *Nat Genet.* 2013;45:25–33. DOI: 10.1038/ng.75
30. Goyal Sh., Tanigawa Y., Zhang W., et al. APOC3 genetic variation, serum triglycerides, and risk of coronary artery disease in Asian Indians, Europeans, and other ethnic groups. *Lipids Health Dis.* 2021; 20: 113. DOI: 10.1186/s12944-021-01531-8
31. Alexopoulos A., Qamar A., Hutchins K., et al. Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes. *Curr Diab Rep.* 2019 Feb 26; 19(4): 13. DOI: 10.1007/s11892-019-1136-3
32. Hirano T. Pathophysiology of Diabetic Dyslipidemia. *Journal of Atherosclerosis and Thrombosis,* 2018, 25(9):771–782. DOI: 10.5551/jat.rv17023
33. Chen AH, Tseng CH. The role of triglyceride in cardiovascular disease in asian patients with type 2 diabetes—a systematic review. *Rev Diabet Stud.* 2013;10(2–3):101–9. DOI: 10.1900/RDS.2013.10.101
34. Xiaofeng Ye, Wen Kong, Mohammad Ishraq Zafar, and Lu-Lu. Serum triglycerides as a risk factor for cardiovascular diseases in type 2 diabetes mellitus: a systematic review and meta-analysis of prospective studies. *Cardiovasc Diabetol.* 2019; 18: 48.
35. Børge G Nordestgaard. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. *Circ Res.* 2016 Feb 19;118(4):547–63. DOI: 10.1161/CIRCRESAHA.115.306249
36. Simental-Mendia LE, Rodriguez-Moran M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. *Metab Syndr Relat Disord.* 2008;6:299–304.
37. Navarro-Gonzalez D, Sanchez-Inigo L, Pastrana-Delgado J, Fernandez-Montero A, Martinez JA. Triglyceride-glucose index (TyG index) in comparison with fasting plasma glucose improved diabetes prediction in patients with normal fasting glucose: the Vascular-Metabolic CUN cohort. *Prev Med.* 2016;86:99–105.
38. Lee SB, Ahn CW, Lee BK, et al. Association between triglyceride glucose index and arterial stiffness in Korean adults. *Cardiovasc Diabetol.* 2018;17:41.
39. Kim MK, Ahn CW, Kang S, et al. Relationship between the triglyceride glucose index and coronary artery calcification in Korean adults. *Cardiovasc Diabetol.* 2017;16:108.
40. Ramdas Nayak VK, Satheesh P, Shenoy MT, Kalra S. Triglyceride glucose (TyG) index: a surrogate biomarker of insulin resistance. *J Pak Med Assoc.* 2022;72(5):986–8. DOI: 10.47391/JPMA.22–63
41. Khalaji A., Behnoush H., Khanmohammadi Sh. Triglyceride-glucose index and heart failure: a systematic review and meta-analysis. *Cardiovasc Diabetol.* 2023; 22: 244. DOI: 10.1186/s12933-023-01973-7
42. Fagenholz PJ, Castillo CF, Harris NS, Pelletier AJ, Camargo CA. Increasing United States hospital admissions for acute pancreatitis, 1988–2003. *Ann Epidemiol.* 2007;17:491–497. DOI: 10.1016/j.annepidem.2007.02.002
43. Wang S, Li S, Feng Q, Feng X, Xu L, Zhao Q. Overweight is an additional prognostic factor in acute pancreatitis: a meta-analysis. *Pancreatology.* 2011;11:92–98. DOI: 10.1159/000327688
44. Bradley EL. A clinically based classification system for acute pancreatitis summary of the international symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. *Arch Surg.* 1993;128:586–590. DOI: 10.1001/archsurg.1993.01420170122019
45. Singh VK, Bollen TL, Wu BU et al. An assessment of the severity of interstitial pancreatitis. *Clin Gastroenterol Hepatol.* 2011;9:1098–1103. DOI: 10.1016/j.cgh.2011.08.026
46. Banks PA, Freeman ML. Practice Parameters Committee of the American College of Gastroenterology. Practice guidelines in acute pancreatitis. *Am J Gastroenterol.* 2006;101:2379–2400. DOI: 10.1111/j.1572-0241.2006.00856.x
47. van Santvoort HC, Bakker OJ, Bollen TL et al. A conservative and minimally invasive approach to necrotizing pancreatitis improves outcome. *Gastroenterology.* 2011;141:1254–1263. DOI: 10.1053/j.gastro.2011.06.073
48. Rashid MU, Hussain I, Jehanzeb S, Ullah W, Ali S, Jain AG, et al. Pancreatic necrosis: complications and changing trend of

- (EFLM) Joint Consensus Initiative Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. *Clin Chem Lab Med.* 2020; 58(4): 496–517. DOI: 10.1515/cclm-2019-1253
76. Pearson RC, Cogan B, Garcia SA, Jenkins NT. Effect of Prior Exercise on Postprandial Lipemia: An Updated Meta-Analysis and Systematic Review. *Int J Sport Nutr Exerc Metab.* 2022;32(6):501–518. DOI: 10.1123/ijsnem.2022-0043
77. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 11<sup>th</sup> Ed. M. 2023. Russian (Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 11-й вып. М.; 2023). DOI: 10.14341/DM13042
78. Fan W, Philip S, Granowitz C, Toth PP, Wong ND. Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk by Statin Use in U.S. Adults With Diabetes: National Health and Nutrition Examination Survey 2007–2014. *Diabetes Care.* 2019;42(12):2307–2314.
79. Gurevich V.S., Koziolova N.A., Ezhov M.V., et al. Unsolved problems of dyslipidemia and residual cardiovascular risk. *Atherosclerosis and dyslipidemia* 2022; 1(46): 31–39. Russian (Гуревич В.С., Козиолова Н.А., Ежов М.В. и соавт. Нерешенные проблемы дислипидемии и резидуального сердечно-сосудистого риска. *Атеросклероз и дислипидемии.* 2022; 1(46): 31–39).
80. Toth P.P. Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. *Vascular Health and Risk Management.* 2016.12: 171–183.
81. Halcox J.P. et al. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study *BMC Cardiovasc Disord.* 2017. 17(1): 160.
82. Myerson M. *Dyslipidemia. A Clinical Approach.* Wolters Kluwer. Philadelphia. 2019.
83. Feher MD, Caslake M, Foxton J, et al. Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronized fenofibrate. *Diabetes Metab. Res. Rev.* 1999; 15: 395–399.
84. Jun M, Foot C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. *Lancet.* 2010; 375(9729): 1875–1888.
85. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. *Lancet.* 2001; 357(9260):905–910. DOI: 10.1016/S0140-6736(00)04209-4
86. Millan J, Pintó X, Brea A, Blasco M. et al. Antonio Hernández-Mijares, Juan Ascaso, Angel Diaz, Teresa Mantilla, Juan Pedro-Botet. Fibrates in the secondary prevention of cardiovascular disease (infarction and stroke). Results of a systematic review and meta-analysis of the Cochrane collaboration. *Clin Investig Arterioscler.* 2018;30(1):30–35. DOI: 10.1016/j.arteri.2017.11.001
87. Pradhan A.D., Glynn R. J., Jean-Charles Fruchart Sc. et al., for the PROMINENT Investigators. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. *N Engl J Med* 2022; 387:1923–1934. DOI: 10.1056/NEJMoa2210645
88. Jones P.H. et al. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials *Am J Cardiovasc Drugs.* 2010. 10(2): 73–84.
89. Roth E.M. et al. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study. *Am J Cardiovasc Drugs.* 2010. 10(3): 175–186.
90. Gogolashvili NG, Yaskevich RA. Omega-3 polyunsaturated fatty acids in modern cardiology practice. Krasnoyarsk, 2012. Russian (Гоголашвили Н.Г., Яскевич Р.А. Омега-3 полиненасыщенные жирные кислоты в современной кардиологической практике. Красноярск, 2012.)
91. Davidson M.H. et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study *Clin Ther.* 2007. 29(7): 1354–1367.
92. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. *N Eng J Med.* 2019; 380: 11–22.
93. Abdelhamid A S, Brown TJ, Brainard JS, et al. Cochrane Heart Group. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. *Cochrane Database Syst Rev.* 2020; 2020(3): DOI: 10.1002/14651858.CD003177.pub5
94. Khan S.U., Lone A.N., Khan M.S. et al. Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis. *E Clinical Medicine.* 2021; 38: 100997. DOI: 10.1016/j.eclinm.2021.100997
95. von Eckardstein, Binder C. J. (eds.). *Prevention and Treatment of Atherosclerosis, Handbook of Experimental Pharmacology* 270, Springer. DOI: 10.1007/164\_2020\_353
96. Graham MJ, Lee RG, Bell TA 3<sup>rd</sup>, et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. *Circ Res.* 2013;112(11):1479–1490. DOI: 10.1161/CIRCRESAHA.111.300367
97. Witztum J.L., Gaudet D., Freedman S.D. et al. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. *N Engl J Med.* 2019 Aug 8; 381(6):531–542. DOI: 10.1056/NEJMoa1715944
98. Gaudet D, Alexander VJ, Baker BF et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. *N Engl J Med.* 2015;373(5):438–447. DOI: 10.1056/NEJMoa1701329
99. Gouni-Berthold I. The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia.

- Atherosclerosis. 2017; Suppl 30:19–27. DOI: 10.1016/j.atherosclerosis.2017.05.003
100. D'Erasmus L., Gallo A., Costanzo A.D. et al. Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia. *Expert Opinion on Pharmacotherapy*. 2020; 21(14):1675–1684. DOI: 10.1080/14656566.2020.1787380
101. Digenio A, Dunbar RL, Alexander VJ, et al. Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes. *Diabetes Care*. 2016;39(8):1408–1415. DOI: 10.2337/dc16-0126
102. Graham MJ, Lee RG, Brandt TA, et al. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. *N Engl J Med*. 2017;377(3):222–232.
103. Gaudet D, Gipe DA, Pordy R, et al. ANGPTL3 inhibition in homozygous familial hypercholesterolemia. *N Engl J Med*. 2017; 377(3):296–297. DOI: 10.1056/NEJMc1705994
104. Santos R.D., Duel P.B., East C. et al. Mittleman. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. *Eur Heart J*. 2015; 36(9): 566–575. Published online 2013 Dec 23. DOI: 10.1093/eurheartj/ehf549
105. Stefanutti C, Chan DC, Di Giacomo S, Morozzi C, Watts GF. Long-Term Efficacy and Safety of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia: Real-World Clinical Experience. *Pharmaceuticals (Basel)*. 2022 Nov 11;15(11):1389. DOI: 10.3390/ph15111389
106. Ahmad Z, Pordy R, Rader DJ et al. Inhibition of Angiotensin-Like Protein 3 With Evinacumab in Subjects With High and Severe Hypertriglyceridemia. *J Am Coll Cardiol*. 2021 Jul 13;78(2):193–195. DOI: 10.1016/j.jacc.2021.04.091
107. Željko R. Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy. *Korean Circ J*. 2018 Dec; 48(12): 1097–1119. Published online 2018 Oct 31. DOI: 10.4070/kcj.2018.0343
108. Meyers Ch., Tremblay K., Amer A. et al. Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome. *Lipids Health Dis*. 2015; 14: 8. DOI: 10.1186/s12944-015-0006-5
109. Gryn SE, Hegele RA. Novel therapeutics in hypertriglyceridemia. *Curr Opin Lipidol*. 2015; 26:484–491.
110. Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolemia: a single-arm, open-label, phase 3 study. *Lancet*. 2013; 381:40–46.
111. Azhigirova M.A., Belozerskaya G.G., Berkovsky A.L. et al. *Essays on Industrial and Clinical Transfusiology, M., 2006. 500–510. Russian (Ажигирова М.А., Белозерская Г.Г., Берковский А.Л. и др. Очерки по производственной и клинической трансфузиологии, М., 2006. 500–510 с.)*
112. Diagnosis and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. *Russian recommendations. V Revision. Atherosclerosis and dyslipidemia*. 2012. 4: 5–52. Russian (Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. V Пересмотр. Атеросклероз и дислипидемии. 2012. 4: 5–52).
113. Konovalov G.A., Abramov S.Yu., Zvezdkin P.V. et al. Extracorporeal methods of correction of metabolic disorders. *Kremlin medicine. Clinical Bulletin*. 2002. 2: 9–13. Russian (Коновалов Г.А., Абрамов С.Ю., Звездкин П.В. и др. Экстракорпоральные методы коррекции метаболических нарушений. Кремлевская медицина. Клинический вестник. 2002. 2: 9–13).
114. Konovalov G.A. Immunosorption and rheopheresis in clinical practice. *Achievements and prospects. New Medical Technologies in Outpatient Practice: Materials of the Scientific and Practical Conference Dedicated to the 10th Anniversary of the Medsi Medical Center*. 2006. 7–11. Russian (Коновалов Г.А. Иммуносорбция и реоферез в клинической практике. Достижения и перспективы. Новые медицинские технологии в поликлинической практике материалы научно-практической конференции, посвященной 10-летию работы Медицинского центра Медси. 2006. 7–11).
115. Ruderman MI, Palmer RH, Olarte MR, et al. Rowland Tarsal tunnel syndrome caused by hyperlipidemia. Reversal after plasmapheresis. *Arch Neurol*. 1983; 40:124–125.
116. Betterigl DJ, Bakowski M, Taylor KG et al. Treatment of severe diabetic hypertriglyceridemia by plasmapheresis. *Lancet*. 1978; 1:1368.
117. Karneeva O.V., Konovalov G.A., Doroshchenko N.E., Smolnikov V.S. The use of hemapheresis methods in otorhinolaryngology. *Kremlin medicine. Clinical Bulletin*. 2002. 2: 60–61. Russian (Карнеева О.В., Коновалов Г.А., Дорошенко Н.Э., Смольников В.С. Применение методов гемафереза в оториноларингологии. Кремлевская медицина. Клинический вестник. 2002. 2: 60–61).
118. Voinov V.A., Goldfarb Yu.S., Konovalov G.A., et al. *Clinical Use of Extracorporeal Methods of Treatment. M., 2006. 105–107, 125–126. Russian (Воинов В.А., Гольдфарб Ю.С., Коновалов Г.А. и др. Клиническое применение экстракорпоральных методов лечения, М., 2006. 105–107, 125–126).*
119. Gerard A, Schooneman F, Guine TM et al. Plasmapheresis treatment of a patient with hyperlipidemia and diabetic ketoacidosis with focal pulmonary edema and acute pancreatitis. *Vox Sang*. 1982. 43: 147–150.
120. Dau P.C., Cardella C.J., Taft E.G., *Therapeutic Plasma Exchange Disease Compendium, COBE Laboratories*. 1983. 141–143 с.
121. Konovalov G.A., Chebyshev A.N., Zvezdkin P.V. et al. Extracorporeal methods in the treatment of severe forms

- of atherosclerosis, metabolic syndrome and dilated cardiomyopathy. Kremlin medicine. Clinical Bulletin. 2001 4: 48–54. Russian (Коновалов Г.А., Чебышев А.Н., Звездкин П.В. и др. Экстракорпоральные методы в лечении тяжелых форм атеросклероза, метаболического синдрома и дилатационной кардиомиопатии. Кремлевская медицина. Клинический вестник. 2001. 4: 48-54).
122. Kononov G.A., Filonenko I.V., Akopyan V.S. et al. Rheopheresis in clinical practice. 2004. 3: 48–53. Russian (Коновалов Г.А., Филоненко И.В., Акопян В.С. и др. Реоферез в клинической практике. Кремлевская медицина, Клинический вестник. 2004. 3: 48–53).
123. Filonenko I.V., Akopyan V.S., Kononov G.A. et al. Assessment of the ocular and preocular optic nerves in patients with anterior ischemic optic neuropathy before and after a course of plasmapheresis. Kremlin medicine. Clinical Bulletin. 2002. 2: 51–54. Russian (Филоненко И.В., Акопян В.С., Коновалов Г.А., Грешнова О.Б., Альбицкая Е.В., Харлап С.И. Оценка состояния окулярного и преокулярного отделов зрительного нерва у пациентов с передней ишемической оптической невропатией до и после курса плазмафереза. Кремлевская медицина. Клинический вестник. 2002. 2: 51–54).
124. Aljouda L., Nagy L., Schulze A. Long-Term Treatment of Lipoprotein Lipase Deficiency with Medium-Chain Triglyceride-Enriched Diet: A Case Series. *Nutrients*. 2023; 15(16): 3535. DOI: 10.3390/nu15163535